

Ref: STEX/OUTCOME/2025-26

Date: 12.08.2025

BSE Limited 25th Floor Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400 001 BSE Code-531146	National Stock Exchange of India Limited Exchange Plaza, C-1, Block - G Bandra Kurla Complex Bandra (East) Mumbai – 400 051 NSE Code: MEDICAMEQ
--	--

Sub. : Outcome of Board Meeting

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended on June 30, 2025.

Pursuant to Regulation 30 & 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- a) Statement showing the Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2025 as **Annexure-A** and
- b) Limited review Report on the Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2025 as **Annexure-B**

Further Board of Directors at their meeting approved the following resolutions:

- c) Approved draft Annual Report for the financial year 2024-25.
- d) Appointment of Mr. Ashwani Kumar Sharma (DIN: 00325634) as Whole-time Director to be designated as Executive Director of the Company for a period of five years.
- e) Appointment of Mr. Sham Goel (DIN: 02183287) as Non-Executive Independent Director of the Company.
- f) Appointment of Mr. Shaival Saurabh (DIN: 01971944) as Non-Executive Independent Director of the Company.

- g) The 32nd AGM of the Company will be held on Friday the September 26, 2025 at 12.00 Noon through Video Conference (VC)/ Other Audio-Visual Means (OAVM) facility.

Pursuant to rule 20(4)(vii) of the Companies (Management and Administration) Rules, 2014, the Company has fixed Friday, September 19, 2024 as the cut-off date for the purpose of determining the eligible shareholders (holding shares either in physical or dematerialized form) to cast their vote electronically from Tuesday, September 23, 2025 to Thursday, September 25, 2025.

In compliance of SEBI (LODR), Regulations, 2015 the Board of Directors of the Company have decided to close the Register of Members and other Transfer books of the Company with a view to enable the Company to make payment of Final Dividend @10% or Re. 1 per Equity Share (if decided by the members in their forthcoming AGM) for the Financial year 2024-25. The aforesaid register will remain close from Friday, September 19, 2025 to Thursday September 25, 2025 (both days inclusive).

The requisite details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/0155 dated 11th November, 2024 in respect of appointment and Change in designation are given in enclosed **Annexure-C**.

Please note that the reports of Auditors are with unmodified opinion with respect to the Un-audited Financial Results of the Company for the quarter ended June 30, 2025.

The meeting of the Board of Directors commenced on 02.00 p.m. and concluded at 03.30 p.m.

The Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2025, as approved by the Board, will also be available on the Company's website www.medicamen.com.

This is for your information and records.

Thanking You.

Yours faithfully,

For Medicamen Biotech Limited

Parul Choudhary
Company Secretary
ACS44157

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, Website: www.medicamen.com

Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th June '2025

	Particulars	Standalone				Consolidated			
		Three Month period Ended		Year Ended	Three Month period Ended		Year Ended		
		30.06.2025 Unaudited	31.03.2025 Audited	30.06.2024 Unaudited	31.03.2025 Audited	30.06.2025 Unaudited	31.03.2025 Audited	30.06.2024 Unaudited	31.03.2025 Audited
1	Income from operations (a) Net Sales / Income from operations (b) Other Income (c) Total Revenue	3,844.90 47.03 3,891.93	2,599.54 521.95 3,121.50	4,148.17 57.52 4,205.69	15,146.33 622.51 15,768.85	4,304.48 47.03 4,351.50	2,961.29 522.73 3,484.02	4,304.86 58.63 4,363.49	16,254.72 624.39 16,879.10
2	Expenses a) Cost of Material Consumed b) Purchase of Goods Traded c) Changes in Inventory of Finished Goods and Work in Progress d) Employees Benefits Expenses e) Finance Cost f) Depreciation and Amortisation Expenses g) Other expenses Total Expenses	2,387.78 (188.49) 530.53 56.24 177.30 711.65 3,675.00	1,091.04 213.54 552.28 62.27 47.52 852.11 2,818.77	2,142.37 237.71 547.87 67.85 174.21 734.17 3,904.18	8,883.33 (608.08) 2,157.02 304.54 696.21 3,058.38 14,491.41	2,459.77 (188.49) 809.03 115.34 180.13 762.63 4,138.41	1,151.73 224.73 839.81 64.99 48.80 905.85 3,235.89	2,166.57 242.61 783.55 70.57 177.03 767.53 4,207.86	9,064.97 (603.17) 3,187.29 315.61 706.61 3,219.80 15,891.10
3	Profit/(Loss) before Exceptional Items & Tax (1-2)	216.94	302.72	301.51	1,277.43	213.09	248.12	155.63	988.00
4	Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-
5	Profit/(Loss) before Extra Ordinary Items & Tax (3-4)	216.94	302.72	301.51	1,277.43	213.09	248.12	155.63	988.00
6	Tax Expenses Current Year MAT Credit Entitlement Deferred Tax Liability	56.96 (3.68) 53.27	72.57 (9.64) 62.93	83.56 (7.80) 75.76	363.95 (31.25) 332.70	56.96 (3.91) 53.05	72.57 (9.64) 62.93	83.56 (7.80) 75.76	363.95 (31.52) 332.43
7	Net Profit / Loss for the period from Continuing operation (5-6)	163.66	239.79	225.75	944.73	160.05	185.19	79.87	655.57


R. Bhatnagar

Particulars	Standalone				Consolidated			
	Three Month period Ended		Year Ended		Three Month period Ended		Year Ended	
	30.06.2025 Unaudited	31.03.2025 Audited	30.06.2024 Unaudited	31.03.2025 Audited	30.06.2025 Unaudited	31.03.2025 Audited	30.06.2024 Unaudited	31.03.2025 Audited
8 Other Comprehensive Income								
Item that will not reclassified to Profit & Loss								
9 Total Comprehensive Income net of Tax	163.66	239.79	225.75	944.73	160.05	185.19	79.87	655.57
10 Net Profit /Loss attributable to								
a) Controlling Interest								
b) Non-controlling Interest					215.30 (55.25)	240.44 (55.25)	135.12 (55.25)	710.82 (55.25)
10 Paid up equity share capital								
(Rs. 10/- per share)								
11 Earning Per Share (Rs.)								
Basic	1.356.28	1,271.46	1,271.46	1,271.46	1,356.28	1,271.46	1,271.46	1,271.46
Diluted	1.21	1.89	1.78	7.43	1.18	1.46	0.63	5.16
	1.21	1.89	1.78	7.43	1.18	1.46	0.63	5.16

NOTES :

- 1 The unaudited financial results for the quarter ended on 30.06.2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12th August, 2025
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 3 The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- 4 The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share"
- 5 Audit Report has been carried out by the Statutory Auditors for the above period.
- 6 The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

or & on behalf of Board of Directors
Medicamen Biotech Limited



Place : New Delhi
Dated : 12.08.2025

RAI QIMAT & ASSOCIATES

CHARTERED ACCOUNTANTS



LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY STANDALONE FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To
The Board of Directors,
Medicamen Biotech Ltd.
1506, Chiranjiv Tower, 43
Nehru Place, New Delhi-110019

We have reviewed the accompanying statement of unaudited financial results of M/s Medicamen Biotech Limited having its registered office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter ended on June 30, 2025 and year to date results for the period from April 01, 2025 to June 30, 2025 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time ("the Listing Regulation").

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS - 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 read with Regulation 63(2) of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

Place: Gurugram
Date: 12.08.2025

For RAI QIMAT & ASSOCIATES
Chartered Accountants
QIMAT RAI GARG
Partner
(Membership Number: 013152C)
UDIN: 25080857BMLCQP8061

**LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY CONSOLIDATED
FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER
REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE
REQUIREMENTS) REGULATIONS, 2015**

To

The Board of Directors,
Medicamen Biotech Ltd.
1506, Chiranjiv Tower, 43
Nehru Place, New Delhi-110019

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of MEDICAMEN BIOTECH LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its subsidiaries for the quarter ended on June 30, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.


5. The Statement includes the results of the Opal Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited (the "Subsidiary" Company)
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 and 7(ii) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and

measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. The Statement includes the Group's share of net profit/(loss) after tax of Rs. (3.62) Crores for the quarter ended on June 30, 2025, as considered in the consolidated unaudited financial results, in respect of its subsidiaries, based on their interim financial information which has not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial informations are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

Our conclusion on the Statement is not modified in respect of the above matter.

For Rai Qimat & Associates
Chartered Accountants



(Membership Number: 013152C)
UDIN: 25080857BMLCQQ7845

Place: Gurugram
Date: 12.08.2025

ANNEXURE-A**1. APPOINTMENT OF INDEPENDENT DIRECTORS OF THE COMPANY**

Particulars	Mr. Sham Goel (DIN: 02183287)	Mr. Shaival Saurabh (DIN: 01971944)
Reason for Change viz. appointment	<p>The term of Mr. Harish Pande and Mr. Arun Kumar, Independent Directors of the Company, will be expiring on February 26, 2026 on completion of 2 consecutive terms of 5 years each. Therefore, to comply with the provisions of Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to fill the vacant position, the Company is required to appoint 2 Independent Directors on or before expiration of their term.</p> <p>Hence, in compliance with the provisions of Sections 149, 150 and 152 and other applicable provisions of the Companies Act, 2013 ("Act") and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and on the recommendation of the Nomination and Remuneration Committee (NRC) and subject to the approval of shareholders, the Board of Directors in its meeting held on August 12, 2025 approved the appointment of Mr. Sham Goel & Mr. Shaival Saurabh as an Additional Directors in an Independent Category for the first term of 5 (Five) years, effective from August 12, 2025.</p>	
Effective Date of appointment	August 12, 2025	August 12, 2025
Term of appointment	5 Years	5 Years
Brief Profile	<p>Mr. Sham Goel is a qualified Chartered Accountants having more than 30 years of experience in the field of Finance, taxation and accounts. Currently Mr. Goel is Director in Essem Logistics Limited (formerly known as Essem Mercantile Ltd). His core competence includes financial analysis and taxation matters.</p> <p>Mr. Goel has earned his Commerce degree from Punjab University, Chandigarh and completed Chartered Accountant programme in the year 1993.</p>	<p>Mr. Shaival Saurabh is a Graduate having over 30 year of rich experience in branding and advertising. He has helped both small and large corporates to achieve brand growth by creating the vision, mission, goals and strategies and plans for their brands. His key role has been in analyzing brand positioning in the market, develop effective messaging and communication strategies, measure performance of marketing campaigns, monitor market trends and find new growth strategies.</p> <p>He has helped in branding and communication of Companies like</p>

		Jindal Stainless Limited, Price WaterHouse Coopers, Jubilant Group, DB Schenker, Star Worldwide, DPauls, 1 India Family Mart, Cornitos, Attd'inox and Elegant Auto among others
Disclosure of relationships between Directors	No relationship exist with any other Directors/ KMP	No relationship exist with any other Directors/ KMP
Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/ 2018-19 dated 20th June 2018 and National Stock Exchange of India Limited Circular no. NSE/CML/2018/02 dated June 20, 2018	Mr. Sham Goel is not debarred from holding the office of director by virtue of any SEBI order or any other such Authority.	Mr. Shaival Saurabh is not debarred from holding the office of director by virtue of any SEBI order or any other such Authority.

2. CHANGE IN DESIGNATION : APPOINTMENT OF MR. ASHWANI KUMAR SHARMA FROM NON-EXECUTIVE DIRECTOR TO WHOLE TIME DIRECTOR DESIGNATED AS EXECUTIVE DIRECTOR

Particulars	MR. ASHWANI KUMAR SHARMA
Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise	Change in category of Mr. Ashwani Kumar Sharma from Non-Executive Director of the Company to a Whole Time Director designates as an Executive Director of the Company, subject to approval of the Members.
Effective Date of appointment	Change in category will be effective from August 12, 2025
Term of appointment	5 Years
Brief Profile	Mr. Ashwani Kumar Sharma is a Graduate, possessing rich experience in managing Supply chain activities of Shivalik Rasayan Limited.

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Disclosure of relationships between Directors	Mr. Ashwani Kumar Sharma is not related to any other Director.
Information as required pursuant to BSE circular with ref No LIST/COMP/14/2018-19 and the National Stock Exchange of India Ltd with ref No NSE/CM/2018/24 dated June 20, 2018	Mr. Ashwani Kumar Sharma is not debarred from holding the office of director by virtue of any SEBI order or any other such Authority on the Board of the Company.